Draegerwerk AG & Co. KGaA (DRW8) AI Stock Analysis
Top Page
Draegerwerk AG & Co. KGaA
(BX Swiss:DRW8)
No summary available
Draegerwerk AG & Co. KGaA (DRW8) vs. iShares MSCI Switzerland ETF (EWL)
- Market Cap
- CHF 1.35B
- Dividend Yield
- ―
- Average Volume (3M)
- 60
- Price to Earnings (P/E)
- 11.3
- Beta (1Y)
- -0.45
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Switzerland
- Employees
- 16,687
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Draegerwerk AG & Co. KGaA Business Overview & Revenue Model
Company Description
Headquartered in Lübeck, Germany, and established in 1889, Drägerwerk AG & Co. KGaA is a global provider of advanced medical and safety technology solutions. The company serves a diverse international clientele across Europe, the Americas, Africa, As...
Draegerwerk AG & Co. KGaA Earnings Call Summary
The call was predominantly positive. Dräger reported strong nine-month order intake, sales, earnings, cash flow, balance-sheet improvement and Safety division momentum, confirmed full-year guidance, and highlighted the lifting of the FDA warning letter and opportunities in defense. These positives were tempered by third-quarter EBIT and Medical performance declines, higher functional expenses, a negative net tariff effect, weaker China demand, Americas and APAC pressure in specific areas, and the need for tight fourth-quarter cost management.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the full year of 2026, Dräger confirmed guidance for net sales growth of 2% to 6%, net of currency effects, and an EBIT margin of 6% to 8%; the target remains unchanged to keep full year expense growth below net sales growth, free cash flow is expected to continue to develop positively, and the company expects order intake and sales to be better for the remainder of the year, with the fourth quarter being the best quarter. The goal to increase defense business from roughly EUR 100 million, which was had in around '25, to around EUR 300 million is unchanged, and the dividend policy remains unchanged at distributing at least 30% of net income as dividend.
Draegerwerk AG & Co. KGaA Peers Comparison
Overall Rating
DE:AFX73Outperform
DE:SHL70Outperform
DE:EUZ69Neutral
DE:M3V66Neutral
DE:SBS56.6Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| DE:AFX | 73Outperform | EUR 3.13B | 20.95 | 5.52% | 1.57% | -0.06% | -38.81% |
| DE:SHL | 70Outperform | EUR 47.86B | 21.66 | 12.00% | 2.33% | -0.92% | 2.06% |
| DE:EUZ | 69Neutral | EUR 832.23M | 16.63 | 19.49% | 1.65% | 4.42% | 35.68% |
| DE:M3V | 66Neutral | EUR 37.13M | 26.84 | 7.77% | 4.66% | -6.92% | -67.82% |
| DE:SBS | 57Neutral | EUR 273.51M | -562.50 | -0.17% | 2.67% | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CH:DRW8 | Draegerwerk AG & Co. KGaA (0MT8) | 68.90 | 1.30 | 1.93% | |
| DE:AFX | Carl Zeiss Meditec | 34.98 | -7.07 | -16.82% | |
| DE:EUZ | Eckert & Ziegler Strahlen und Medizintechnik | 13.30 | -3.09 | -18.88% | |
| DE:M3V | MeVis Medical Solutions | 20.40 | -3.31 | -13.95% | |
| DE:SBS | STRATEC Biomedical | 22.50 | 0.32 | 1.43% | |
| DE:SHL | Siemens Healthineers | 42.89 | -4.78 | -10.03% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.